Introduction
During the course of this conference it has become clear that the application of in vitro, as well as in vivo, models for toxicity might be able to help us a great deal in our efforts to conduct more accurate species-to-species extrapolations of risk. However, the question remains: How do we monitor populations to determine if a particular biochemical pathway might have been perturbed or to determine if a particular population or individual might be sensitive or resistant to the actions of a given chemical?
In our attempts to address this question, the term "surrogate markers" has developed. These are markers which should be reflective of what's happening in the target cell or target organ. The most commonly used surrogate markers have been those that have measured concentrations of a chemical or its metabolites in body fluids or tissues, including urine, blood, and to a lesser extent, hair, milk, placenta, amniotic fluid, and fat. For the purpose of this discussion, it might be useful to classify them together as surrogate markers.
The basis for using markers in risk assessment and human monitoring reflects our growing knowledge of the mechanisms responsible for chemically induced disease. Figure 1 illustrates a general scheme for the sequence of biochemical events that occur between exposure and outcome. It is important to note that without knowledge of mechanism, it is not possible to differentiate between a marker of an exposure and a marker of an effect. Furthermore, the development of susceptibility markers also requires knowledge of mechanism. The appropriate use of susceptibility markers might offer an opportunity to identify individuals at risk and explain the huge interindividual variation in responsiveness to many chemicals. The use of the terms markers of exposure, markers of effect, and markers of susceptibility reflects the definitions used by a recent National Academy of Sciences panel (1 
Cytogenetics
Analyses of sister chromatid exchange (SCE) frequencies and chromosomal aberrations in peripheral human lymphocytes have been conducted in chemically exposed groups. The mechanism responsible for inducing SCEs is not understood; however, many classes of carcinogens and mutagens are known to produce increased SCE frequency. The significance ofthis increase in relation to disease outcome is unclear. Unlike SCE, which 'is an S-phase-specific phenomenon, chromosomal aberrations can occur at any point of the cell cycle. Moreover, there is increasing evidence which suggests that chromosomal aberrations might be linked to the carcinogenic process for some chemicals. Like tests for detecting mutagens in body fluids, cytogenetic analyses might be useful for detecting exposure to complex mixtures but are generally not specific and in many cases not very sensitive.
Gene Mutation
Unlike the previously described assays, gene mutation is the result of direct damage to DNA. Currently, somatic mutation of the HPGRT gene locus in human lymphocytes is being evaluated as a monitoring tool, as is the loss of an allele at the glycophorin A locus in erythrocytes. These assays have been used to detect exposure to cancer chemotherapy agents but have not successfully been applied to environmental exposures. They are in the early stages of development, but do offer the advantage for detecting current as well as past exposures. It remains to be seen what the relationship will be between elevated mutant frequencies at these sites and primary or secondary (in the case of chemotherapy patients) cancer.
An exciting approach for monitoring gene mutation that offers the opportunity to be both sensitive and specific is being developed. It involves enzymatic amplification of mutant gene sequences followed by analysis on gradient denaturing gels (3 
Tumor Markers
Tumor markers have been used to a limited extent. Alpha-fetoprotein has probably been the most widely used marker and has detected early forms ofliver cancer in some populations. The disadvantages of tumor markers is that they are detecting relatively late stages in the carcinogenic process. For the most part, they are neither specific nor sensitive.
Conclusion
In conclusion, unless we understand mechanism of action, the use of surrogate markers is limited to markers of exposure. Without animal models to verify doseresponse relationships, they are also limited. However, the rapid advances in molecular biology may offer tractable approaches to develop tests that are both sensitive, specific, and more predictive of outcome. It, therefore, would seem prudent to collect samples from exposed populations for the purpose DR. RAYMOND TENNANT, NIEHS: I guess the point that you're making and that I tried to make before is in the interspecies extrapolation of data. These are the same types of parameters that one can measure in the short-term assays that I was discussing in my presentation. And I think we can put the best face on this in saying that although we don't understand how much mutagenic activity in the urine becomes significant to the person who is ever going to get a tumor, I think it is still significant that we measure this. And I think it is important to identify what is the mutagenic activity of certain compounds in human tissue or in human urine of exposed individuals. Because even though we don't understand the whole pathway right now, it's certainly worth the effort because the significance of these measurements might be more clear in the future. DR Thank you very much.
